A Multi-dimensional Prospective Study to Discover Gene-microenvironment Interactions in Neurodevelopmental Disorders

A Novel Multi-dimensional Prospective Study of the Gut-brain Axis Through Metabolic MRI, Metabolomics and Gut Microbiome to Discover Gene-microenvironment Interactions in Neurodevelopmental Disorders

This project is the first involving the two most common neurodevelopmental disorders, ASD and ADHD, as well as TDC to establish a multi-dimensional database (clinic, behavior, neurocognitive function, brain imaging, metabolomics, and microbiome) using the same methodology. Based on this integrated multi-dimensional databank, we anticipate exploring metabolic flows of the gut-brain axis during brain development and identifying the common and unique biomarkers of ASD and ADHD and high-risk materials related to their functions and the underlying mechanism. Moreover, distinguishing the characteristics of the gut microbiota, gastrointestinal disorders, and microbial flora dysbiosis also helps us, in turn, to accelerate the process of identifying biological treatments that can interfere or slow down the severity of cognitive impairments in neurodevelopmental disorders. Eventually, we anticipate finding the clinical and neurocognitive measures related to the direct or indirect influence of gut-brain signaling. Our findings are anticipated to improve the knowledge about neurodevelopmental disorders, enhance developing early detection, diagnosis, and treatment for ASD and ADHD, and contribute to precision medicine.

Study Overview

• Status: Recruiting
• Conditions: Autism Spectrum Disorder; Attention-Deficit Hyperactivity Disorder, Unspecified Type
• Intervention / Treatment: Other: ASD diagnosis; Other: Psychiatric diagnosis

Detailed Description

Autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD) are common neurodevelopmental disorders in Taiwan and worldwide (prevalence rate, ASD, 1%; ADHD, 3-10%), presenting as clinically and genetically heterogeneous disorders with early onset at childhood lasting to adulthood. Both disorders bring a tremendous impact on individuals, families, and society. Despite extensive studies on these two disorders, our knowledge about their pathogenetic mechanism is still minimal, and there are no biomarkers for effective prevention, early detection, diagnosis and biological treatment (ineffective in 30% ADHD patients, none for ASD). Although they have distinct symptom inclusion criteria and intervention, emerging evidence suggests that ASD and ADHD may share some genetic influences and susceptibility involving neuroanatomical phenotypes, cognitive deficits, and behavioral phenotypes. However, few studies have investigated these two disorders simultaneously. Moreover, the role of metabolomics and microbiome in neuropsychiatric disorders has drawn much attention recently. With the PI's long-term commitment to the neurocognitive/imaging/gene research ADHD and ASD in separate projects, our knowledge about these two disorders improved, but their underlying pathogenesis remains unclear. Hence, a multi-dimensional prospective gut-brain axis integration study highlighting the metabolism in the whole body to identify the common and unique factors of these two disorders and discover their gene-microenvironment interaction mechanism is extremely urgent and warranted.

Specific Aims:

1. To identify and compare the early environmental factors (e.g., maternal, and pre-, peri-, and post-natal factors) affecting the gut- microbiome, cognition, and brain structures and functions among the ASD, ADHD and TDC groups at ages of 4-12 years old;
2. To investigate the symptomatology, neuropsychology, neuroimaging, gut microbiome and metabolic biomarker signatures at Time 1 and Time 2 among the three groups while considering food, GI symptoms, and life style;
3. To investigate the changes (Time2-Time1), stability, and interactions of the symptomatology, neuropsychology, neuroimaging (MRI+MRS), gut microbiome and metabolic biomarker signatures in youths with ASD and ADHD as compared to TDC over a 2-4-year follow-up period.
4. To identify the predictors from the environmental (perinatal, food, lifestyle, family, school, neighborhood) and individual (behavior, gut microbiota, metabolomics, brain structure) factors for the neurocognitive/brain function and psychosocial outcomes in the follow-up.

• Study Type: Observational
• Enrollment (Estimated): 360

Contacts and Locations

Study Locations

• Taiwan
  • Taipei, Taiwan
    • Recruiting
    • National Taiwan Univeristy Hospital
    • Contact: Susan Shur-Fen Gau, MD, PhD; Phone Number: 66802 886-2-23123456; Email: gaushufe@ntu.edu.tw

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 5 years to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

120 ASD and 120 ADHD, aged 4-18 will be recruited from the Department of Psychiatry, National Taiwan Univeristy Hospital(NTUH), or the participants with ASD or ADHD from Taiwan's National Epidemiological Study of Child Mental Disorders (TNESCMD). 120 age-, and sex-matched typically developing controls (TDC) will be recruited from the same geographic areas of the ASD/ADHD groups via referral by teachers or the invitation of participants without any psychiatric disorders.

Description

Inclusion Criteria:

• Clinical diagnosis of autism spectrum disorder or attention-deficit hyperactivity disorder defined by the DSM-5 criteria, made by board-certificated child psychiatrists
• Ages range from 5 to 18
• Both parents are Han Chinese
• Subjects and their parents consented to have repeated assessments at 2 to 3 years later

Exclusion Criteria:

• Comorbidity with DSM-5 diagnoses of ADHD (TDC group), ASD (ADHD and TDC groups), schizophrenia, schizoaffective disorder, delusional disorder, other psychotic disorders, organic psychosis, schizotypal personality disorder, bipolar disorder, depression, severe anxiety disorders or substance use
• Comorbidity with neurological or systemic disorders
• Having a first degree relative who may have ASD based on family history method assessment (ADHD and TDC groups)

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
ASD group; 120 ASD patients (aged 5-18 years)	Other: ASD diagnosis; Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS); Other: Psychiatric diagnosis; Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
ADHD group; 120 ADHD patients (aged 5-18 years)	Other: Psychiatric diagnosis; Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
TDC group; 120 age-, and sex-matched typically developing controls (TDC) will be recruited from the same geographic areas of the ASD/ADHD groups via referral by teachers or the invitation of participants without any psychiatric disorders	Other: Psychiatric diagnosis; Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Neuropsychological functions: Continuous Performance Test(CPT)	The 4 dimensions of CPT: focused attention, hyperactivity/impulsivity, sustained attention, and vigilance	15 minutes
Neuropsychological functions: Cambridge Neuropsychological Test Automated Batteries(CANTAB)	The 4 main cognitive components of CANTAB: Visual Memory, Attention, Working and Planning Memory (Executive Functions), and Decision Making	1.5 hours
Structural neuroimaging: Diffusing spectrum imaging (DSI)	DSI is performed using a pulsed-gradient spin-echo diffusion echo planar imaging (EPI) sequence with 102 diffusion-encoding directions	1 hour
Multi-echo resting-state fMRI (rfMRI)	rfMRI will be used to evaluate resting-state connectivity	1 hour

Collaborators and Investigators

• Sponsor: National Taiwan University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2021
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: May 4, 2021
• First Submitted That Met QC Criteria: May 4, 2021
• First Posted (Actual): May 7, 2021

Study Record Updates

• Last Update Posted (Actual): October 17, 2023
• Last Update Submitted That Met QC Criteria: October 16, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Attention Deficit and Disruptive Behavior Disorders; Child Development Disorders, Pervasive; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Neurodevelopmental Disorders
• Other Study ID Numbers: 201903105RINB

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No